Extension Study to Establish Safety, Pharmacokinetics and Efficacy of BIBF 1120 in Patients With Previous Clinical Benefit From BIBF 1120.
Phase of Trial: Phase I
Latest Information Update: 19 Dec 2014
At a glance
- Drugs Nintedanib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 31 Aug 2018 Biomarkers information updated
- 15 Jan 2010 Actual number of patients (41) added as reported by ClinicalTrials.gov.
- 15 Jan 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.